As a result of the merger, Zynerba became a wholly owned subsidiary of Harmony. The common stock of Zynerba will no longer be listed for trading...
6 months ago

The Offer was initially scheduled to expire at 5:00 p.m. New York City time on September 26, 2023. As of that time, approximately 32.1% of...
7 months ago

Under the deal, Harmony will initiate a tender offer for all outstanding Zynerba shares at $1.1059 per share in cash. Additionally, the...
8 months ago

Following its Scorpion Capital controversy in March, Harmony Biosciences is seeking to deepen its pipeline with an acquisition of Zynerba...
8 months ago

Zynerba Pharmaceuticals Inc. allegedly misled investors about financial aspects of its proposed merger with Harmony Biosciences Holdings...
7 months ago

Neurological drug developer Harmony Biosciences markets a narcolepsy product that isn't scheduled as a controlled substance like others for...
8 months ago

Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today? · Shares of cannabinoid therapeutics developer Zynerba Pharmaceuticals (ZYNE) popped...
8 months ago

Harmony Biosciences announced a definitive agreement to acquire Zynerba Pharmaceuticals on Aug. 14, 2023, where Harmony will acquire all...
8 months ago

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its...
5 days ago

14, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and...
8 months ago